Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia (NCT04251910) | Clinical Trial Compass
CompletedPhase 1/2
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
United States100 participantsStarted 2019-12-27
Plain-language summary
This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL-501 dosing in adult (65 years and older) males and females with acute agitation associated with dementia. Evaluation of 3 doses are planned.
Who can participate
Age range65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male and female patients 65 years and older.
* Patients who have dementia and a history of acute agitation.
* History of agitation that requires intervention or impairs social or daily activities
* Patients who meet International Psychogeriatric Association (IPA) diagnostic criterion for agitation.
* Patients with a total score of ≥ 8 on the Pittsburgh Agitation Scale (PAS).
* Patients who have a score of ≥ 2 on at least 1 of the 4 items on the Pittsburgh Agitation Scale (PAS).
* Patients who read, understand and provide written informed consent, or who have a Legally Authorized Representative (LAR).
* Patients who are in good general health.
Exclusion Criteria:
* For Part B: Patients with dementia associated with Parkinson's disease and/or Lewy Body Disease, if etiology of dementia is known.
* Patients with agitation caused by acute intoxication.
* Patients treated within 4 hours prior to study drug administration with benzodiazepines, other sedatives, hypnotics or oral or short-acting intramuscular antipsychotics must be excluded.
* Treatment with alpha-1 noradrenergic blockers, alpha adrenergic antagonists within 8 hours prior to dosing.
* No new chronic medications initiated in the past 14 days prior to screening excluding over-the-counter products taken sporadically.
* Patients at significant risk of harm to themselves or others
* Patients considered medically unstable or in recovery
* Patients with history of clinically significant syncope or sy…
What they're measuring
1
Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score